Apimeds Pharmaceuticals US (APUS) Cash from Operations (2024 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Cash from Operations came in at -$3.8 million in Q4 2025, down 3732.92% on a YoY basis from $105100.1 in Q4 2024, and down 121.2% quarter-over-quarter from -$1.7 million in Q3 2025.
Powered by 
Analysis
Apimeds Pharmaceuticals US (APUS) Cash from Operations (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has reported Cash from Operations for 2 consecutive years, with -$3.8 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Cash from Operations fell 3732.92% year-over-year to -$3.8 million; the trailing twelve-month figure through Dec 2025 stood at -$8.9 million (down 1116.83% YoY), and the FY2025 full-year result was -$8.9 million, down 1116.83% from the prior year.
- Cash from Operations declined to -$3.8 million in Q4 2025 per APUS's latest filing, from -$1.7 million in the prior quarter.
- Across five years, Cash from Operations topped out at -$20313.0 in Q1 2025 and bottomed at -$3.8 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 4.00 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 3.57 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.13 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 813.00 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -526.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 448.90 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Apimeds Pharmaceuticals US | 3.65 Mn | 3.65 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -3.82 Mn |
| Sep 30, 2025 | -1.73 Mn |
| Jun 30, 2025 | -3.36 Mn |
| Mar 31, 2025 | -20,313.00 |
| Dec 31, 2024 | -99,616.00 |
| Sep 30, 2024 | -186,755.00 |
| Jun 30, 2024 | -184,055.00 |
| Mar 31, 2024 | -263,100.00 |